The state of Iowa currently has 4 active clinical trials seeking participants for COPD research studies. These trials are conducted in various cities, including Iowa City, Des Moines, Sioux City and Cedar Rapids.
SPIROMICS Study of Early COPD Progression (SOURCE)
Recruiting
This is an observational study of 1000 participants to further define the nature of early chronic obstructive pulmonary disease (COPD) in younger, at-risk individuals. The study has three main goals: To use CT scan imaging to identify which smokers will develop COPD. To identify biomarkers predictive of smokers that will develop COPD. To determine if sputum (phlegm) can be analyzed to predict which smokers will develop COPD. Procedures (methods): All participants will undergo study related qu... Read More
Gender:
All
Ages:
Between 30 years and 55 years
Trial Updated:
03/25/2024
Locations: University of Iowa, Iowa City, Iowa
Conditions: COPD, Early-Onset
Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
Recruiting
Subjects who completed either OBERON or TITANIA will be offered the opportunity to consent for this Multicentre, Double-blind, Randomised, Placebo controlled, Parallel Group, Phase 3, extension study to evaluate the safety and efficacy of Tozorakimab in adult participants with symptomatic COPD.
Gender:
All
Ages:
Between 40 years and 130 years
Trial Updated:
03/19/2024
Locations: Research Site, Iowa City, Iowa
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
Recruiting
The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab Dose 1 and Dose 2 administered subcutaneously (SC) in adult participants with symptomatic COPD and history of ≥ 2 moderate or ≥ 1 severe exacerbation of COPD in the previous 12 months. Participants should be receiving optimised treatment with maintenance inhaled therapy (ICS/LABA/LAMA triple therapy, or dual therapy if triple is not considered appropriate) in stable doses throughout at least 3 months prior... Read More
Gender:
All
Ages:
Between 40 years and 130 years
Trial Updated:
03/07/2024
Locations: Research Site, Iowa City, Iowa
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
COPD-Related Physiology and the Brain
Recruiting
COPD is the third leading cause of combined morbidity, disability, and mortality in the United States and is often associated with cognitive impairment. The goal of the proposed project is to examine novel pulmonary and vascular physiological mechanisms that contribute to structural brain abnormalities and cognitive dysfunction early in the course of COPD. The project will generate information to ultimately inform the development of interventions to delay or prevent cognitive dysfunction.
Gender:
All
Ages:
Between 30 years and 85 years
Trial Updated:
11/06/2023
Locations: Carinda Linkenmeyer, Iowa City, Iowa
Conditions: Pulmonary Disease, Chronic Obstructive (COPD), Cognitive Impairment